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Abstract 
No bulking agent is ideal for endoscopical-
ly  treating  vesico-renal  reflux  in  children.
Many teams have tried to find a safe and effi-
cient material, ideally an autologous material.
We  describe  here  a  protocol  for  the  use  of
autologous viable fat in the treatment of pri-
mary  vesico-renal  reflux  in  children  aged
from 3 to 15 years. Fat harvesting was done
from the medial side of the thigh by manual
aspiration. Samples were centrifuged to puri-
fy the graft from blood and lipid. Lastly fat was
injected beneath the pathologic ureter by a
conventional endoscopic technique. A voiding
cystourethrography (VCUG) closed the proce-
dure. Follow-up included renal ultrasonogra-
phy the day after surgery, and one and three
months later. A VCUG was performed system-
atically at three months and, in cases of acute
pyelonephritis, during the survey.
Sixty-four children with 94 refluxing units
were treated by autologous fat injection with a
follow-up from 6 to 40 months. At the end of
the procedure, we systematically obtained a
very good increase in height of the pathologic
meatus  and  VCUG  was  normal  in  all  cases.
None  presented  with  an  obstruction  during
the follow-up period. Two children presented
with an acute pyelonephritis before the third
month. At three months, VCUG was not real-
ized in 14 cases (22%) because the parents
refused the procedure. One of those children
presented  with  an  acute  pyelonephritis  five
months after endoscopic treatment. VCUG was
normal  for  17  of  50  children  (34%),  and
showed a real improvement for 19 other chil-
dren  (38%).  Three  children  had  a  surgical
reimplantation because of the persistence of
an unchanged high-grade vesico-renal reflux;
histological  examination  found  viable
adipocytes on sections of the distal pathologic
ureter. Clinically, 11 children (17%) presented
with an acute pyelonephritis after treatment
at a mean follow-up time of 10 months.
These preliminary findings led us to modi-
fy  the  technique  in  order  to  improve  our
results.  Our  first  concern  is  feasibility  and
safety of this technique, regardless of the use
of other synthetic bulking agents the innocu-
ousness of which is uncertain.
Introduction
Acute  pyelonephritis  (APN)  is  a  common
problem in childhood and is associated with
vesico-renal reflux (VRR) in 25-40% of chil-
dren.
1 Persistent  VRR  and  repeated  pyelo-
nephritis may predispose to renal scars and
chronic renal failure with an end-stage renal
failure in up to 3% of cases.
1 Defining a stan-
dard treatment for VRR in children is not easy
because  of  the  lack  of  reliable  evidence.
Numbers of studies prospectively or retrospec-
tively compare medical, endoscopic, and surgi-
cal treatments.
2-4 Moreover, numbers of low-
grade VRR have a spontaneous resolution. 
Surgical techniques are effective but inva-
sive and not free of complications while med-
ical treatment is dependent on close observa-
tion.  The  introduction  of  endoscopic  tech-
niques  permits  the  prevention  of  new  APN
and renal failure by VRR elimination. Since
the beginning of the use of endoscopic treat-
ment, several bulking agents have been pro-
posed.  The  ideal  agent  should  be  easy  to
inject, stable in time, and safe,
5 and at least as
efficient as the actual bulking agent. The use
of Teflon was the first success of endoscopic
treatment, despite the problem of migration.
6-11
Since then many substances have been pro-
posed,  autologous  or  exogenous,  resorbable
or not. However, none was ideal and no solu-
tion was found for the problem of biocompat-
ibility or long-term stability.
12,13 Using adipose
tissue as a bulking agent is an ancient prac-
tice in plastic surgery and, in the last century,
Coleman introduced a new technique called
“lipostructure”.
14 This technique has lead to a
growing interest in its use in the restoration
of  all  volume  defects  in  plastic  surgery
because of the stability of the graft. We pro-
posed to apply this technique to VRR manage-
ment in children, thus combining innocuous-
ness and efficacy.
Materials and Methods
To be included in the study, patients must
be aged from 3 to 15 years and have primary
VRR stage II or III. They must not have had
endoscopic treatment or localized surgery in
the  past.  We  proposed  this  technique  after
failure  or  refusal  of  medical  treatment.  A
dimercaptosuccinic  acid  (DMSA)  scan  was
done preoperatively in cases of recurring APN
or if renal scars were seen on ultrasonogra-
phy  (US).  Oral  and  written  information  on
the  technique  were  given  systematically.  If
the legal representative of the child refused,
or if the child did not fulfill all conditions, the
child  was  excluded.  If  the  parent/guardian
agreed with this technique and if the child
met all the conditions of inclusion, consent
was signed. 
The first step of the procedure was fat har-
vesting of the patient’s own adipose tissue.
The  donor  site  was  the  medial  side  of  the
thigh (Figure 1). The patient was in a gyne-
cological position on the operation table and
the procedure was performed under general
anesthesia. We needed a cannula and a 10 mL
syringe  for  a  standard  lipoaspiration.
Purification of the autologous fat graft was
obtained by centrifugation (Figure 2), after
which  we  separated  the  intermediate  layer
containing  viable  adipocytes  and  their
fibrovascular  stroma  from  blood  (inferior
layer) and lipid (superior layer). The second
step  of  the  procedure  was  the  endoscopic
treatment  of  VRR.  Adipocytes  were  trans-
ferred in several 1 mL syringes, which were
placed  successively  in  a  ratchet  gun.  The
technique for subureteral injection was stan-
dard using a needle through the endoscope
(Figure 3). The graft was injected below the
ureteral meatus, positioned ideally according
to the STING procedure. To close the proce-
dure, we systematically carried out an imme-
diate voiding cystourethrography (VCUG) to
complete the injection in case of persistent
reflux.  Patients  had  renal  US  the  day  after
surgery  to  detect  any  obstruction,  and  one
and  three  months  later.  Efficacy  was  con-
firmed on VCUG three months after the proce-
dure when an adipocyte graft is considered as
stable. Any APN during the follow-up period
necessitated VCUG and DMSA. A DMSA was
not systematically done during the follow-up
period but only in cases of a new APN within
two months after infection, or on the appear-
ance of renal scars on US.
Pediatric Reports 2009; volume 1:e7
Correspondence:  Isabelle  Lacreuse,  Pediatric
Surgeon, Hôpitaux Universitaires de Strasbourg, 
1  place  de  l'hôpital,  BP  426,  67091  Strasbourg
Cedex,  France.  E-mail:  isabelle.talon2@chru-
strasbourg.fr
Key words: autologous graft, adipocytes, vesico-
renal reflux.
Received for publication: 22 June 2009.
Revision received: 16 October 2009.
Accepted for publication: 19 October 2009.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0).
©Copyright I. Lacreuse et al., 2009
Licensee PAGEPress, Italy
Pediatric Reports 2009; 1:e7
doi:10.4081/pr.2009.e7[page 24] [Pediatric Reports 2009; 1:e7]
Results
Currently,  64  children  with  94  refluxing
units have benefited from this technique with
a follow-up from 6 to 40 months. We treated 57
girls and 7 boys with a mean age of 7.8 years.
Thirty of them had a bilateral VRR. All VRRs
were diagnosed after one or several APNs. We
decided to treat only VRR grade II or III. Three
patients had a complementary injection dur-
ing  the  procedure  because  of  a  persistent
reflux on VCUG.
Of  the  patients,  50  had  VCUG  at  three
months (78%), of which 17 (34%) were com-
pletely  cured  on  VCUG,  19  (38%)  were
improved with the persistence of a minor radi-
ological reflux but no recurrent infection dur-
ing  the  follow-up  period.  Thirteen  patients
(26%) refused VCUG at three months. Among
them,  one  patient  presented  with  APN  five
months  after  the  procedure.  In  three  cases
(6%), VCUG was exactly the same as before
the treatment. As these patients had severe
pyelonephritis with renal scars before treat-
ment, we decided to do a surgical reimplanta-
tion. Viable adipocytes without any necrosis
were found microscopically. For the 11 other
children with VCUG at three months, improve-
ment was considered as minor (22%). Of the
refluxing  units,  41%  were  cured,  24%  were
improved,  18%  were  unchanged,  and  17%
were not explored by VCUG at three months.
US was done at one and three months and has
enabled confirmation of the persistence of the
bulking agent even if its volume seemed to be
lower than on the day after surgery. 
Clinically,  among  the  patients  without
VCUG at three months, one had APN at five
months and refused any exploration or treat-
ment of a possible reflux. Among the patients
cured  on  VCUG  at  three  months,  three
(17.6%) had APN during the follow-up (two at
one  year  and  one  at  two  years).  Only  one
patient  accepted  VCUG,  which  was  normal.
Since then, follow-up was uneventful. Among
the patients who improved by this treatment,
three (15.7%) had APN six to 12 months later
and  two  of  them  had  a  second  endoscopic
treatment with another bulking agent. Finally,
among  the  failures  of  this  technique  (14
patients), four (28%) had APN, three had a
reimplantation because of renal scars before
treatment, and two had a second endoscopic
treatment with another bulking agent. None
of  the  children  had  an  obstruction  or  new
renal  scar  on  renal  US  or  on  DMSA  scans
when done. No complication, particularly no
pain or bleeding, concerning the donor site of
fat was reported. The majority of the children
and their legal representatives were satisfied
with the technique and result.
Discussion
The introduction of fat as a bulking agent in
surgery  dates  from  1889  when  Van  Der
Meulen
15 treated a diaphragmatic hernia with
epiploon.  Using  autologous  fat  in  surgery
became common from 1910 to 1977.
16-19 Illouz
introduced  lipoaspiration  in  1977,  and  great
progress was the introduction by Coleman of
the notion of atraumatic manipulation of fat.
In  1997  he  published  his  technique  called
lipostructure:  the  harvesting,  purification  by
centrifugation,  and  reinjection  of  fat.
14 After
this, it was evident that autologous fat grafts
need gentle manipulation of the tissue to pre-
Article
Figure1.  Donor  site  on  the
medial side of the thigh.
Figure  2.  Purification  by
centrifugation.
Figure 3. Endoscopic injec-
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serve  the  viability  of  the  adipocytes.  Since
then,  many  more  surgeons  have  tried  this
technique in their fields of competence.
20 The
main  argument  against  fat  grafting  was  its
lack of stability, but MacRae et al. have demon-
strated that centrifugation and gentle manipu-
lation of fat had no significant effect on fat via-
bility.
21,22
Since  the  beginning  of  endoscopic  treat-
ment of VRR, many bulking agents have been
tried. Several studies have compared different
agents to determine the ideal one but none
combined  all  the  conditions  to  become  the
standard. Simultaneously, Santiago et al. and
Matthews  et  al.  used  autologous  fat  for  the
treatment of urinary incontinence.
23,24 Results
were not satisfying owing to instability issues,
but they did not apply Coleman’s technique.
Furthermore,  no  study  mentions  this  tech-
nique of autologous adipocyte grafts in endo-
scopic treatment of VRR.
Our unit has applied the endoscopic treat-
ment of VRR since 1983. Until 2000, we used
Teflon; since 2001, we have preferred polydi-
methylsiloxane. Our clinically good results are
around 85%, as reported in the literature. After
the problems of Teflon migration we examined
the stability of this resorbable agent. For this
reason we considered another bulking agent
which  could  defer  biocompatibility,  stability,
efficiency and cost-effectiveness. Concerning
biocompatibility, this technique is guaranteed
because we use autologous tissue. As regards
stability, studies have proved a radiological sta-
bilization of about 50% of the initial volume
three  months  after  injection.
25 Histological
analysis  of  grafts  has  shown  persistence  of
mature adipocytes
26-28 several years after sur-
gery.  Lastly,  autologous  adipocyte  grafts
allowed money-saving by a reduction of dispos-
ables.  
This preliminary study shows 34% of good
results but 64% of persistent reflux (improved
or unchanged) with a few cases of new APN
but  no  new  renal  scars.  This  is  satisfactory
clinically but we have to improve our radiolog-
ical results. No complication has been diag-
nosed on US and clinical follow-up. We agree
with the fact that radiological classification is
not satisfactory with regard to VRR but, for the
moment, it is the only objective criterion to
evaluate the efficiency of a new bulking agent.
We decided to treat VRR staged II or III because
of the large evidence base for endoscopic treat-
ment in the advanced stages of VRR. For this
study, we injected a mean of 0.4 mL of fat in
one  site,  which  seems  to  be  insufficient.
Because of volume loss we have to inject at
least 1 mL of fat in several sites under each
pathologic  ureter.  Indeed,  viability  of  the
adipocyte graft is compromised in the case of
too voluminous a graft, when the large area of
vascularization of the middle of a voluminous
graft leads to apoptosis of the cells.
18 Moreover,
we decided to give up the STING procedure for
intraureteral injection after hydrodistension of
the  ureter.  In  this  way  we  began  a  second
cohort of patients and we improved our clinical
and radiological results. However, the follow-
up  period  is  too  short  to  conclude  that  the
improvement is statistically significant.  
Conclusion
Autologous adipocyte grafts for endoscopic
treatment of VRR in children is a potentially
satisfactory approach. It is feasible, safe, and
provides good results on the mid-term follow-
up.  The  biocompatibility  of  the  autologous
adipocyte graft and the theoretical long-term
stability of this viable graft lead us to publish
our research findings. We recently improved
our  technique  by  injecting  more  autologous
adipocytes in several points in the ureter after
its hydrodistension. We are waiting for results
from  this  second  cohort.  Although  it  is  too
early to draw conclusions, our first results do
not  lead  us  to  suggest  that  the  autologous
adipocyte graft is any closer to the ideal bulk-
ing agent. 
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